ABBV-1451

ABBV-1451 is a monoclonal antibody developed by AbbVie that targets **Blood Dendritic Cell Antigen 2 (BDCA2)**, also known as **CLEC4C**. BDCA2 is a receptor specifically expressed on the surface of plasmacytoid dendritic cells (pDCs), which are the primary producers of Type I interferons (IFN-I). By binding to BDCA2, ABBV-1451 is designed to internalize the receptor and suppress the production of IFN-I and other pro-inflammatory cytokines. This mechanism is highly relevant for the treatment of autoimmune diseases such as **systemic lupus erythematosus (SLE)** and **cutaneous lupus erythematosus (CLE)**, where pDC activation and excessive IFN-I signaling are central to disease pathogenesis. As of 2024, ABBV-1451 is in Phase 1 clinical development, with studies evaluating its safety and pharmacokinetics in healthy volunteers, including specific cohorts of Japanese and Han Chinese subjects.